Published in Cancer Weekly, August 15th, 2006
The cancer-research community has long recognized LPA as a significant contributor to cancer through its promotion of cancer-cell growth and metastasis in a broad range of tumor types. In response, many academics, biotechs, and pharmaceutical companies have all tried - without success - to produce drugs, including antibodies, that target LPA and neutralize its potent tumorigenic effects.
Using its proprietary ImmuneY2 technology, Lpath has not only succeeded in generating monoclonal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.